The present multicenter randomized study investigates whether the management of patients with parkinsonism by a nurse specialist (case-manager) can significantly improve patients' quality of life over 12 months, compared to control patients managed with the standard-of-care process. Participants will be evaluated with clinical scales testing quality of life, motor and non-motor symptoms, and the number of unscheduled hospital access throughout the course of the study.
Several studies provide evidence that a multidisciplinary management of individuals with Parkinson's disease (PD) including a specialized nurse may offer significant benefits to patients, in the management of disability due to motor and non-motor symptoms as well as in monitoring compliance to therapy and incident adverse events. A number of retrospective studies demonstrated that frequent neurologic consultations and a strict adherence to pharmacological therapy can reduce the risk of hospitalization up to 50%. Falls, fractures, infections and cognitive and motor deterioration represent risk factors for hospitalization in patients with PD. These complications are even more frequent in patients affected by atypical parkinsonisms (e.g. multiple system atrophy and progressive supranuclear palsy). The optimization of management of motor and non-motor symptoms and pharmacological side effects, through telemedicine services carried out by nurses specialized in movement disorders, can prevent falls and hospitalization, increase quality of life and reduce comorbidities and caregiver's burnout. In the present study, a "case-manager" will follow-up patients and caregivers, cooperating at the same time with other members of a multidisciplinary team (neurologists, psychologists, physiatrists, general practitioners, social assistants), either within or outside the institute where the neurologist visits, aiming to achieve a better global management of frail patients. The present multicenter, randomized, double-blind study will recruit 164 patients affected by Parkinson's disease, atypical parkinsonism or secondary parkinsonism with motor and/or non motor complications, living in the Lombardy region (Northern Italy). Patients will be enrolled in a tertiary referral clinic with expert knowledge ('hub': Fondazione IRCCS Istituto Neurologico Carlo besta) and in a community hospital ('spoke': Azienda Socio Sanitaria Territoriale Nord Milano). The participants will be randomized into two treatment arms: (i) the interventional arm (patients followed by a case manager); (ii) the control arm (the standard-of-care). At the baseline and at the visits at 6 and 12 months, clinical scales and questionnaires will be administered to determine if there are differences between the quality of life and the disability of patients between the two arms of treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Enrollment
121
Patients are followed up by a nurse specialist in parkinsonism (case manager) who interacts with the treating neurologist and a multidisciplinary team
Patients are managed only by the neurologist according the institution's clinical practice
Azienda Socio-Sanitaria Territoriale Nord Milano
Sesto San Giovanni, Milan, Italy
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy
Changes in total score of the Parkinson's Disease Questionnaire 39-items scale
Thi is a 39-items questionnaire assessing the quality of life of patient with Parkinson's disease. The higher the score the lower the quality of life
Time frame: baseline, week 52
Number of unscheduled hospital access over the 12-month study period
The investigators will collect the sum of the number of (i) extra unscheduled outpatient visits, (ii) emergency room visits, (iii) hospital admissions directly or indirectly associated with parkinsonism
Time frame: baseline, week 26, week 52
Changes in the Movement Disorder Society Unified Parkinson's Disease Rating Scale part II
This is a scale (MDS-UPDRS) used to assess activities of daily living. The higher the score the worse the Disability
Time frame: baseline, week 52
Changes in the Movement Disorder Society Unified Parkinson's Disease Rating Scale part IV
This is a scale (MDS-UPDRS) used to assess complications of dopaminergic therapy. The higher the score the worse the disability
Time frame: baseline, week 52
Changes in the Non-Motor Symptoms Scale score
This is a scale used to assess the burden of non-motor symptoms in Parkinson's disease. The higher the score the worse the disability
Time frame: baseline, week 52
Changes in the activities of daily living questionnaire
The "ADL (Activities of Daily Living)" evaluation refers to the fundamental activities of daily life in which the subject is dependent: on a scale from 0 to 6 points, the lower the score, the greater the person's need for assistance
Time frame: baseline, week 52
Changes in the instrumental activities of daily living questionnaire
The "IADL (Instrumental Activities of Daily Living)" evaluation refers to the instrumental activities of daily life in which the subject is dependent (eg using telephone, preparing meals, taking medications, etc): on a scale from 0 to 8 points, the lower the score, the greater the person's need for assistance
Time frame: baseline, week 52
Changes in patient experience questionnaire
This is a questionnaire assessing patient perception and satisfaction of the quality of health care
Time frame: baseline, week 26, week 52
Changes in EuroQOL-5 Dimensions-5 Levels score
This is a useful and validated instrument to measure quality of life in patients with Parkinson's disease
Time frame: baseline, week 52
Changes in the Morisky Medical Adherence scale-8 items score
This is an 8-items scale used to investigate patient adherence to the therapy prescribed by the MD specialist
Time frame: baseline, week 26, week 52
Changes in the Zarit Burden Interview scale score
This is a scale used to investigate caregiver's burnout
Time frame: baseline, week 26, week 52
Number of incident comorbidities
The number of incident comorbidities over the 12.month study period will be assessed using a semistructured interview
Time frame: baseline, week 26, week 52
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.